robertnowinski.easyjournal.com/rss/robertnowinski.xml -
[Cached Version]
Published on: 8/26/2008
Last Visited: 8/26/2008
Robert Nowinski has founded six biotechnology companies.He subsequently brought four of these companies public through an IPO financing.He was the first employee in each company and also held the executive position(s) of CEO and/or the Chairman of the Board.In each business he set the direction, acquired the initial technology, recruited key management and provided oversight for the research programs.Dr. Robert Nowinski also conducted private and public financings of up to $130 million for each company.Three of the public companies have been acquired by major pharmaceutical companies; Genetic Systems in 1987 for $310 million by Bristol-Myers; PathoGenesis in 2000 for $660 million by Chiron/Novartis; and Icos in 2006 for $2.2 billion by Eli Lilly.The fourth public company, VaxGen, is traded on NASDAQ.Collectively, these companies have developed and marketed eight diagnostic tests and two therapeutic drugs with annual sales exceeding $2.0 billion. Robert Nowinski received his Ph.D. in immunology from the Sloan-Kettering Institute in 1971.From 1971 to 1975 he was an assistant professor of oncology at the University of Wisconsin.From 1975 through 1981, he was an associate professor of microbiology and immunology at the University of Washington.He also was a founding scientist and head of the Virology Program of the Fred Hutchinson Cancer Research Center in Seattle.From 1981 through 1982, Robert Nowinski was a professor of microbiology at the UW and a member of the FHCRC.His academic research concerned cancer-causing retroviruses, as well as antibody treatments for cancer and antibodies for the diagnosis of sexually-transmitted diseases. In 1981, Dr. Robert Nowinski began a second career in the biotechnology industry when he founded Genetic Systems Corp. in Seattle.Genetic Systems conducted an IPO financing within one month of its formation.The company developed diagnostic products and treatments for infectious diseases and cancer.From 1981 through 1985,Robert Nowinski was the company's chairman and CEO. Genetic Systems developed the first rapid test for Chlamydia, the most prevalent sexually-transmitted disease in humans.This test decreased the average time of diagnosis from 21 days to 45 minutes, lowered the cost of diagnosis from $150 to $4.50 and expanded the U.S. market from 150,000 tests per year to an estimated 20 million.In collaboration with the Institut Pasteur, Genetic Systems then developed the most accurate blood test for HIV within the first generation of HIV diagnostics. In 1983, within the structure of Genetic Systems, Dr. Robert Nowinski founded the subsidiary Oncogen LP, dedicated solely to cancer diagnostics.Oncogen, located in the Genetic Systems Building, was co-owned and solely financed by Syntex Corp.In 1985, Genetic Systems and Syntex each sold one-third of their interests to Bristol-Myers Corp. and the mandate of Oncogen was expanded to include cancer therapeutics. In 1986, Dr. Robert Nowinski initiated and managed the merger of Genetic Systems and Oncogen LP into Bristol-Myers through a pooling of interests valued at $310 million.Dr. Robert Nowinski was appointed corporate vice president for New Technology at Bristol-Myers and chairman of the new Genetic Systems Division.At that time he relocated from Seattle to the corporate headquarters of Bristol-Myers in New York. In 1989, Dr. Robert Nowinski returned to Seattle and founded Icos Corp.Dr. Robert Nowinski served as CEO of Icos from 1989 to 1991.In 1991, he brought Icos public.The company focused on inflammation and novel methods for drug discovery.Icos developed the drug Cialis for treating erectile dysfunction.Eli Lilly markets Cialis, with annual sales exceeding $1.2 billion.In 2006, Icos was acquired by E. Lilly for $2.2 billion.In 1992, Dr. Robert Nowinski founded PathoGenesis.The company focused on the cause and treatment of chronic illnesses.Dr. Robert Nowinski served as chairman of PathoGenesis from 1992 to 1995 and as chairman emeritus for several years thereafter.In 1993, he brought PathoGenesis public.In 1997, PathoGenesis received FDA approval to market an aerosolized form of tobramycin, or TOBI, for treating cystic fibrosis.In addition, research within PathoGenesis identified HerpesVirus 6 as a primary causative agent of multiple sclerosis.In August 2000, PathoGenesis was acquired by Chiron Corp. for $660 million.TOBI is now the leading treatment for cystic fibrosis; annual sales exceed $600 million.Chiron was subsequently acquired by Novartis. In 1995, Dr. Robert Nowinski founded VaxGen.VaxGen develops preventive vaccines for infectious diseases.He served as VaxGen's chairman and CEO until 2000.Dr. Robert Nowinski brought VaxGen public in 1998.VaxGen completed the first Phase 3 trial of an HIV vaccine, or AIDSVAX.AIDSVAX was tested in 8,500 volunteers on three continents.The trial, completed in January 2003, reported that the vaccine was ineffective.Although 100% of vaccine-recipients developed antibodies, the rate of HIV infection was similar in the vaccinated and placebo groups.VaxGen has since developed vaccines against anthrax and smallpox. In 2000, Dr. Robert Nowinski founded and became chairman and CEO of Primal Inc.
...
Primal is currently in the business of developing new drugs to GPCRs.In 2008, Dr. Robert Nowinski moved to New York and founded ContraFect Corporation.href="http://www.zoominfo.com/people/Nowinski Robert 3539342.aspx">Robert Nowinski at ZoominfoRobert Nowinski at robertnowinski.comhref="http://www.robertnowinski.org/">Robert Nowinski at robertnowinski.orgRobert Nowinski at robertnowinski.nethref="http://www.ziggs.com/apps/profile/bio.aspx?uid=5923
2">Robert Nowinski at ZiggsTue, 19 Aug 2008 16:31:29 GMT
Copyright 2005, Easyjournal on behalf of robertnowinskiEasyjournalRobert Nowinskihttp://robertnowinski.cman.easyjournal.com/entry.aspx?eid=3735602Ro
bert Nowinski, a scientist with a doctorate in immunology and a flairfor creating new businesses, has combined those talents to found sixbiotechnology companies.Four of these companies were eventually takenpublic, and several were acquired by larger corporations.In eachbusiness, Robert Nowinski determined the direction, acquired theinitial technology, recruited key management and provided oversight forthe research programs.Robert Nowinski also ensured the continuinghealth of the companies by conducting private and public financings ofup to $130 million for each one.Education and Early Career MovesRobert Nowinski received his Ph.D. in immunology from theSloan-Kettering Institute in 1971.From 1971 to 1975 he was anassistant professor of oncology at the University of Wisconsin, afterwhich he served as associate professor of microbiology and immunologyat the University of Washington through 1981.Dr. Robert Nowinski alsowas a founding scientist and head of the Virology Program of the FredHutchinson Cancer Research Center in Seattle.His academic researchfocused on cancer-causing retroviruses, antibody treatments for cancerand antibodies for the diagnosis of sexually-transmitted diseases. Genetic Systems Corp.In 1981, Dr. Robert Nowinski began a second career in the biotechnologyindustry when he founded Genetic Systems Corp., Seattle.GeneticSystems conducted an IPO financing within one month of its formation.The company developed diagnostic products and treatments for infectiousdiseases and cancer.From 1981 through 1985, Dr. Robert Nowinski wasthe company’s chairman and CEO. Genetic Systems developed the first rapid test for Chlamydia, the mostprevalent sexually-transmitted disease in humans.This test decreasedthe average time of diagnosis from 21 days to 45 minutes, lowered thecost of diagnosis from $150 to $4.50 and expanded the U.S. market from150,000 tests per year to an estimated 20 million.In collaborationwith the Institut Pasteur, Genetic Systems then developed the mostaccurate blood test for HIV within the first generation of HIVdiagnostics. Oncogen LPIn 1983, within the structure of Genetic Systems, Dr. Robert Nowinskifounded the subsidiary Oncogen LP, dedicated solely to cancerdiagnostics.Oncogen
59 online sources [ view sources ]
